Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum InMed Pharmaceuticals Inc INM

InMed Pharmaceuticals Inc. is a clinical-stage pharmaceutical company. The Company is engaged in developing a pipeline of prescription-based products, including rare cannabinoids and cannabinoid analogs, targeting the treatment of diseases with high unmet medical needs, as well as developing proprietary manufacturing technologies to produce rare cannabinoids for sale in the health and wellness... see more

NDAQ:INM - Post Discussion

InMed Pharmaceuticals Inc > Insider Transactions
View:
Post by Bullknit101 on Dec 18, 2020 11:45pm

Insider Transactions

From this week including today:https://ceo.ca/in
Comment by gainwidpatience on Dec 19, 2020 12:40pm
Quiet period is going to be over this week.. need the research articles and analyst ratings to come out. I am quite sure, they will value inmed some where around $200m - $250m.
Comment by kh231 on Dec 19, 2020 6:39pm
60,000 options granted to Bruce Colwill at $3.85 on December 16th!  The fact we closed up on Friday with a high of $4.30, on a down week otherwise --- somebody knows something, and technicals show a Hammer, with near term target $8.00. 
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities